These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27165055)

  • 1. Mechanisms of skin aging induced by EGFR inhibitors.
    Gerber PA; Buhren BA; Schrumpf H; Hevezi P; Bölke E; Sohn D; Jänicke RU; Belum VR; Robert C; Lacouture ME; Homey B
    Support Care Cancer; 2016 Oct; 24(10):4241-8. PubMed ID: 27165055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
    Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
    Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
    Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
    Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.
    Im JS; Herrmann AC; Bernatchez C; Haymaker C; Molldrem JJ; Hong WK; Perez-Soler R
    PLoS One; 2016; 11(7):e0160004. PubMed ID: 27467256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
    Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
    Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T
    BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
    Yamamoto N; Goto K; Nishio M; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Tajima K; Tamura T
    Int J Clin Oncol; 2017 Feb; 22(1):70-78. PubMed ID: 27659294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
    BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
    Perez-Soler R; Zou Y; Li T; Ling YH
    Clin Cancer Res; 2011 Nov; 17(21):6766-77. PubMed ID: 21914790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
    Kriegs M; Gurtner K; Can Y; Brammer I; Rieckmann T; Oertel R; Wysocki M; Dorniok F; Gal A; Grob TJ; Laban S; Kasten-Pisula U; Petersen C; Baumann M; Krause M; Dikomey E
    Radiother Oncol; 2015 Apr; 115(1):120-7. PubMed ID: 25796091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
    Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
    Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
    Kelly K; Altorki NK; Eberhardt WE; O'Brien ME; Spigel DR; Crinò L; Tsai CM; Kim JH; Cho EK; Hoffman PC; Orlov SV; Serwatowski P; Wang J; Foley MA; Horan JD; Shepherd FA
    J Clin Oncol; 2015 Dec; 33(34):4007-14. PubMed ID: 26324372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.